Skip to content
cethromycin

Structure via PubChem · Public domain (PubChem)

EntityQ1057705· pop 8· linked from 109 articles

cethromycin

Sign in to save

Also known as Abbott-195773, A-195773, ABT-773, Restanza

Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

In the Vinony graph

Within Vinony's link graph, cethromycin is referenced by 109 other articles, and connects out to neomycin, liver and antibiotic.

It sits within the topics Chemical pages without DrugBank identifier, Drugboxes which contain changes to verified fields and Drugboxes which contain changes to watched fields.

Its subject is documented across 8 Wikipedia language editions.

Chemical data

Formula
C42H59N3O10
Molecular weight
765.9 g/mol
IUPAC name
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 3
Molecule type
Small molecule
Indications
pneumonia

via ChEMBL · EBI

Wikidata facts

Mass
765.420045
Has use
medication
Show 4 more facts
chemical formula
C₄₂H₅₉N₃O₁₀
subject has role
antibiotic
canonical SMILES
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OCC=Cc4cc5ccccc5nc4)C)C)NC(=O)O2)C
isomeric SMILES
CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC\C=C\c4cc5ccccc5nc4)C)C)NC(=O)O2)C
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

2 sections
Contents
  • References
  • Further reading

Cethromycin, trade name Restanza (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On October 1, 2008, Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.

Excerpted from Wikipedia’s “cethromycin” article, available under the CC BY-SA 4.0 licence.

Available in 8 languages

via Wikidata sitelinks · CC0

Connections

Categories